Trial Profile

A Single-arm, Phase II Study to Evaluate the Efficacy and Safety of Linperlisib (YY-20394) Monotherapy in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 17 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Linperlisib (Primary)
Indications Anaplastic large cell lymphoma; Peripheral T-cell lymphoma; T-cell lymphoma
Focus Therapeutic Use
Sponsors Shanghai Yingli Pharmaceutical

11 Dec 2023 According to a Shanghai Yingli Pharmaceutical media release, the company is looking forward to the results of this trial.
03 Sep 2022 According to Yingli Pharma media release, the trial is in collaboration with The University of Texas MD Anderson Cancer Center. Additional trial sites will include medical centers in the United States and Italy.
03 Sep 2022 According to Yingli Pharma media release, first patient has been dosed in this trial.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com